AU2003287666A1 - Systemic delivery of antiviral agents - Google Patents

Systemic delivery of antiviral agents

Info

Publication number
AU2003287666A1
AU2003287666A1 AU2003287666A AU2003287666A AU2003287666A1 AU 2003287666 A1 AU2003287666 A1 AU 2003287666A1 AU 2003287666 A AU2003287666 A AU 2003287666A AU 2003287666 A AU2003287666 A AU 2003287666A AU 2003287666 A1 AU2003287666 A1 AU 2003287666A1
Authority
AU
Australia
Prior art keywords
antiviral agents
systemic delivery
systemic
delivery
antiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287666A
Other versions
AU2003287666A8 (en
Inventor
Paul Ashton
Jianbing Chen
Thomas J. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Control Delivery Systems Inc
Original Assignee
Control Delivery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Systems Inc filed Critical Control Delivery Systems Inc
Publication of AU2003287666A8 publication Critical patent/AU2003287666A8/en
Publication of AU2003287666A1 publication Critical patent/AU2003287666A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2003287666A 2002-11-13 2003-11-13 Systemic delivery of antiviral agents Abandoned AU2003287666A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42594302P 2002-11-13 2002-11-13
US60/425,943 2002-11-13
PCT/US2003/036637 WO2004043435A2 (en) 2002-11-13 2003-11-13 Systemic delivery of antiviral agents

Publications (2)

Publication Number Publication Date
AU2003287666A8 AU2003287666A8 (en) 2004-06-03
AU2003287666A1 true AU2003287666A1 (en) 2004-06-03

Family

ID=32313080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287666A Abandoned AU2003287666A1 (en) 2002-11-13 2003-11-13 Systemic delivery of antiviral agents

Country Status (2)

Country Link
AU (1) AU2003287666A1 (en)
WO (1) WO2004043435A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AU2008262031B2 (en) 2007-06-08 2011-08-25 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3785683B1 (en) * 2009-05-18 2023-11-01 Dose Medical Corporation Drug eluting ocular implant
CN102740830A (en) * 2009-12-23 2012-10-17 普西维达公司 Sustained release delivery devices
DE202012012956U1 (en) 2011-10-21 2014-10-16 Abbvie Inc. A combination of at least two direct-acting antiviral agents for use in the treatment of HCV, comprising ribavirin but not interferon
UY34401A (en) 2011-10-21 2013-05-31 Abbvie Inc METHODS FOR HCV TREATMENT
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
SG11201608483PA (en) * 2014-05-30 2016-11-29 Textile Based Delivery Inc Drug delivery systems and related methods of use
AU2015339203B2 (en) 2014-10-30 2020-12-24 Textile-Based Delivery, Inc. Delivery systems
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN109937025B (en) 2016-04-20 2022-07-29 多斯医学公司 Delivery device for bioabsorbable ocular drugs
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices

Also Published As

Publication number Publication date
WO2004043435A2 (en) 2004-05-27
AU2003287666A8 (en) 2004-06-03
WO2004043435A3 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2003251323A1 (en) Delivery devices
AU2002322719A1 (en) Delivery of therapeutic capable agents
AU2003298738A1 (en) Liposomal formulations
AU2003224725A1 (en) Hiv therapeutic
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
EP1562557B8 (en) Geodate delivery vehicles
AU2002364893A1 (en) Delivery of medicaments to the nail
AU2003274355A1 (en) Targeted delivery
AU2003287666A1 (en) Systemic delivery of antiviral agents
AU2003211103A1 (en) Intracellular delivery of therapeutic agents
AU2003220968A1 (en) Anti-inflammatory agent
AU2003231947A1 (en) Defensins: use as antiviral agents
AU2003273819A1 (en) Coating agent
AU2003290230A1 (en) Pump-action nozzle arrangements
AU2002339370A1 (en) Nasal Spray
AU2002353510A1 (en) Nebuliser
AU2003292859A1 (en) Feng-you-jing spray
AU2002240942A1 (en) Improved delivery of benefit agents
AU2003289207A1 (en) Anti-inflammatory agent
AU2003290818A1 (en) Topoisomerase-targeting agents
AU2003273803A1 (en) Use of triptans as antiviral agents
AU2002222557A1 (en) Interferon therapeutic effect-potentiating agents
AU2003296961A1 (en) Targeted invitation delivery
AU2003269950A1 (en) Heteroaryl-ethanolamine derivatives as antiviral agents
AU2003207181A1 (en) Microorganism-trapping agent

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase